A serotonin-norepinephrine-dopamine reuptake inhibitor originally studied as an anti-obesity agent. Promotes weight loss through appetite suppression.
Tesofensine was originally studied for neurodegenerative disease and was found to induce weight loss by reducing hunger and increasing satiety, shifting the focus toward obesity treatment.
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine - SNDRI) that modulates appetite, energy expenditure, and motivation.
Most weight-loss trials evaluated oral doses of 0.25, 0.5, and 1 mg/day. 0.5 mg/day showed the most balanced efficacy/tolerability; 1 mg/day produced more weight loss but more side effects.
Side effects increase with dose. Because tesofensine has a very long half-life, adverse effects may persist if the dose is too high.
Somatotropin (176-191)
Fragment 176-191 is a synthetic C-terminal fragment of human growth hormone that promotes fat metabolism. It has shown promise in research for reducing blood sugar and aiding cartilage regeneration.
200-500 mcgTesamorelin and Ipamorelin Blend
A potent growth hormone secretagogue combination. Tesamorelin provides sustained GHRH stimulation while Ipamorelin adds selective GH pulsatility for optimal fat loss and muscle building.
300 mcg/100mcgAnti-Obesity Drug 9604
A synthetic peptide analog of natural AOD-9604 fragment that stimulates lipolysis and inhibits lipogenesis without affecting IGF-1 or insulin.
300 mcg5-Amino-1-Methylquinolinium
A small molecule that inhibits NNMT enzyme, boosting NAD+ levels and cellular energy. Supports fat loss and metabolic function.
1 mg